Skip to main content
. 2020 Aug 5;10:13167. doi: 10.1038/s41598-020-69897-w

Figure 7.

Figure 7

Intranasal delivery of rOVA-3 subunit vaccine plus αGalCer elicits CD8+ TRM responses. B7.2tg mice (n = 5) were primed and boosted i.n. as in Fig. 6. On day 30 after boost, mice were injected i.v. with anti-CD45.2-APC mAb. After 3–5 min., airway cells were collected by perfusing the lungs with PBS. Airway, lungs and spleen single cell suspensions were stained for surface markers and antigen specificity, and gated to identify B8R70–78-specific, CD8+ TRM cells in the airways and lung interstitium (IST TRM), lung CD8+ MV TEM cells, and splenic TCM cells. Expression of surface activation markers was assessed on the indicated populations. Representative gating strategy (A), overlay histograms (B), and geometric mean fluorescent intensity (gMFI) of surface indicated markers on specified populations (C) are shown. Data are cumulative mean ± sem. Airway TRM (n = 2); and IST TRM; MV TEM, TCM: n = 5. ns, not significant (P > 0.05), *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001.